Evidence map›Paper›PMID 31278254›Full record

Observational studyNature communications2019

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.

Malgorzata Czystowska-Kuzmicz, Anna Sosnowska, Dominika Nowis, Kavita Ramji, Marta Szajnik, Justyna Chlebowska-Tuz, Ewa Wolinska, Pawel Gaj, Magdalena Grazul, Zofia Pilch and 13 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 1 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 1 synthesis or guideline pooled it, 305 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 3 countries.

Malgorzata Czystowska-KuzmiczDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.ORCID http://orcid.org/0000-0001-9169-6194
Anna SosnowskaDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.
Dominika NowisDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.ORCID http://orcid.org/0000-0003-2748-9523
Kavita RamjiDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.ORCID http://orcid.org/0000-0002-3667-2146
Marta SzajnikHoly Family Obstetrics and Gynecology Hospital, Warsaw, 02-544, Poland.
Justyna Chlebowska-TuzLaboratory of Experimental Medicine, Center of New Technologies, University of Warsaw, Warsaw, 02-097, Poland.
Ewa WolinskaDepartment of Pathology, Medical University of Warsaw, Warsaw, 02-142, Poland.
Pawel GajLaboratory of Human Cancer Genetics, Center of New Technologies, University of Warsaw, Warsaw, 02-097, Poland.
Magdalena GrazulDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.
Zofia PilchDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.
Abdessamad ZerrouqiDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.ORCID http://orcid.org/0000-0002-2628-473X
Agnieszka Graczyk-JarzynkaDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.
Karolina SoroczynskaDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.ORCID http://orcid.org/0000-0002-4281-1528
Szczepan CierniakDepartment of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, 04-141, Poland.ORCID http://orcid.org/0000-0002-9176-2478
Robert KoktyszDepartment of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, 04-141, Poland.
Esther ElishaevDepartment of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, 15123, PA, USA.
Slawomir GrucaDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland.
Artur StefanowiczDepartment of Gynecology and Obstetrics, "Praski" Hospital, Warsaw, 03-401, Poland.
Roman BlaszczykOncoArendi Therapeutics, Warsaw, 02-089, Poland.ORCID http://orcid.org/0000-0001-7348-9837
Bartlomiej BorekOncoArendi Therapeutics, Warsaw, 02-089, Poland.
Anna GzikOncoArendi Therapeutics, Warsaw, 02-089, Poland.
Theresa WhitesideDepartment of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, 15123, PA, USA.
Jakub GolabDepartment of Immunology, Medical University of Warsaw, Warsaw, 02-097, Poland. jakub.golab@wum.edu.pl.ORCID http://orcid.org/0000-0002-2830-5100
Medical University of Warsaw · PLOncoArendi Therapeutics (Poland) · PLUniversity of Pittsburgh · USUniversity of Warsaw · PLCentral Clinical Hospital · PLMother and Child Foundation · GB

Funding

Restoring anti-tumor immunity in the microenvironment of head and neck cancerR01CA168628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHITESIDE, THERESA L. · 2013 to 2017
$1.7M
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapyR21CA205644 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOYIADZIS, MICHAEL, WHITESIDE, THERESA L. · 2016 to 2017
$370k
Narodowe Centrum Nauki (National Science Centre) 2013/11/B/NZ6/02790Narodowe Centrum Nauki (National Science Centre) 2016/23/B/NZ6/03463NCI NIH HHS R01 CA168628NCI NIH HHS R21 CA205644
6 · The paper itself

Abstract

Tumor-driven immune suppression is a major barrier to successful immunotherapy in ovarian carcinomas (OvCa). Among various mechanisms responsible for immune suppression, arginase-1 (ARG1)-carrying small extracellular vesicles (EVs) emerge as important contributors to tumor growth and tumor escape from the host immune system. Here, we report that small EVs found in the ascites and plasma of OvCa patients contain ARG1. EVs suppress proliferation of CD4

Indexed as

AnimalsArginaseAscitesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell CommunicationCell Line, TumorCell ProliferationCohort StudiesDatasets as TopicDendritic CellsDisease Models, AnimalEnzyme InhibitorsExtracellular VesiclesFemaleHumansARG1 protein, humanArg1 protein, mouseArginaseEnzyme Inhibitors

Identifiers

PMID31278254
PMCPMC6611910
OpenAlexW2956105421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.